A Randomized, Double-blind, Placebo Controlled Study to Assess Efficacy, Safety and Tolerability of LCQ908 in Subjects With Familial Chylomicronemia Syndrome
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01514461 |
Recruitment Status
:
Completed
First Posted
: January 23, 2012
Results First Posted
: June 3, 2015
Last Update Posted
: June 3, 2015
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Familial Chylomicronemia Syndrome (FCS) | Drug: LCQ908 Drug: Placebo | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 45 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Treatment |
Official Title: | A Randomized, Double-blind, Placebo Controlled Study to Assess Efficacy, Safety and Tolerability of LCQ908 in Subjects With Familial Chylomicronemia Syndrome |
Study Start Date : | July 2012 |
Actual Primary Completion Date : | May 2014 |
Actual Study Completion Date : | May 2014 |

Arm | Intervention/treatment |
---|---|
Experimental: LCQ908 20 mg
In period II (0-12 weeks) double-blind treatment: one LCQ908 20 mg active tablet + one LCQ908 placebo matching to 40mg tablet, once daily. No dose titration allowed. In period III (12-52 weeks) double blind treatment: Without down titration, the period II dosing regimen will follow. Following decision to down titrate: one LCQ908 10 mg active tablet + one LCQ908 placebo matching to 40 mg tablet + one LCQ908 placebo matching to 10mg tablets, once daily. A low fat diet will be followed and recorded in patient diary. |
Drug: LCQ908
LCQ908 10 mg, LCQ908 20 mg, LCQ908 40 mg
Drug: Placebo
LCQ908 10 mg, LCQ908 20 mg, LCQ908 40 mg
Other Name: LCQ908
|
Experimental: LCQ908 40 mg
In period II (0-12 weeks) double-blind treatment: one LCQ908 40 mg active tablet + one LCQ908 placebo matching to 20mg tablet, once daily. No dose titration allowed. In period III (12-52 weeks) double blind treatment: Without down titration, the period II dosing regimen will follow. Following decision to down titrate: one LCQ908 20 mg active tablet + one LCQ908 placebo matching to 40 mg tablet + one LCQ908 placebo matching to 10mg tablets, once daily. A low fat diet will be followed and recorded in patient diary. |
Drug: LCQ908
LCQ908 10 mg, LCQ908 20 mg, LCQ908 40 mg
Drug: Placebo
LCQ908 10 mg, LCQ908 20 mg, LCQ908 40 mg
Other Name: LCQ908
|
Placebo Comparator: Placebo
In period II (0-12 weeks) double-blind treatment: one LCQ908 placebo matching to 40mg tablet + one LCQ908 placebo matching to 20mg tablet, once daily. In period III (12-52 weeks) double blind treatment: Without down titration, the period II dosing regimen will follow. Following decision to down titrate: one LCQ908 placebo matching to 40mg tablet + one LCQ908 placebo matching to 20mg tablet + one LCQ908 placebo matching to 10mg tablets, once daily. A low fat diet will be followed and recorded in patient diary. |
Drug: Placebo
LCQ908 10 mg, LCQ908 20 mg, LCQ908 40 mg
Other Name: LCQ908
|
- Percent Change in Fasting Triglycerides From Baseline to 12 Weeks [ Time Frame: Baseline to 12 weeks ]Blood samples were collected for a fasting lipid panel, including triglycerides. If the 12-week value was missing, the measurement value at 12 weeks or the last available post-baseline measurement value during the double-blind treatment period was analyzed. Baseline is defined as the average of fasting triglyceride values taken at day -3 and day 1. Adjusted geometric means are calculated by back-transforming the adjusted means from the model and expressing as a percentage change from baseline.
- Percentage of Patients Responding to Investigational Treatment by Achieving Fasting Triglycerides (TG) of at Least 40% From Baseline or Final Fasting TG < 8.4 mmol/L (750 mg/dL) [ Time Frame: Baseline, 12 weeks, 24 weeks, 52 weeks ]Percentage calculated as (m/n)*100 where m = number of patients who respond; n = the number of patients with non-missing fasting triglyceride.
- Percentage of Patients Responding to Investigational Treatment by Achieving Final Fasting Triglycerides < 8.4 mmol/L (750 mg/dL) [ Time Frame: 12 weeks, 24 weeks, 52 weeks ]Percentage calculated as (m/n)*100 where m = number of patients who respond; n = the number of patients with non-missing fasting triglyceride.
- Percentage of Patients Responding to Investigational Treatment by Achieving Fasting Triglycerides (TG) of at Least 40% From Baseline [ Time Frame: Baseline, 12 weeks, 24 weeks, 52 weeks ]Percentage calculated as (m/n)*100 where m = number of patients who respond; n = the number of patients with non-missing fasting triglyceride.
- Percentage of Patients Achieving Fasting Triglycerides (TG) Target Thresholds [ Time Frame: 12 weeks, 24 weeks, 52 weeks ]Percentage of patients reaching target values of <1000 mg/dL or target values of < 2000 mg/dL for fasting triglycerides is reported. Pecentage calculated as (m/n)*100; where 'm' The number of patients who reach target values for fasting triglyceride, 'n' the number of patients with non-missing fasting triglyceride.
- Percent Change From Baseline in Fasting Triglycerides [ Time Frame: Baseline, 24 weeks, 52 weeks ]
- Percent Change From Baseline for Postprandial Triglycerides Following the Standardized Meal Tolerance Test at Week 12 [ Time Frame: 0-24 hours at Baseline, Week 12 ]Post prandial peak triglycerides - maximum triglyceride value over 0-24 hours Post prandial triglycerides AUC0-24 - area under the time curve for triglycerides over 0-24 Adjusted geometric means are calculated by back-transforming the adjusted means from the model and expressed as a percentage change from baseline. hours
- Pharmacokinetics of LCQ908 - Trough Concentration (Cmin) and Observed Maximum Blood Concentration (Cmax) [ Time Frame: 0, 1, 2, 3, 4, 6, and 24 hours at Week 12 ]Lowest observed blood concentration (Cmin) and observed maximum blood concentration (Cmax) following drug administration derived from non-compartmental analysis using scheduled sampling time for the whole dataset.
- Pharmacokinetics of LCQ908- Area Under the Plasma Concentration Time Curve AUC (0-24hour) [ Time Frame: 0, 1, 2, 3, 4, 6, and 24 hours at Week 12 ]The area under the concentration-time curve from time zero to 24 hours after drug administration was calculated by using linear trapezoidal rule.
- Pharmacokinetics of LCQ908- Time to Reach Maximum Concentration Following Drug Administration Tmax (Hours) [ Time Frame: 0, 1, 2, 3, 4, 6, and 24 hours at Week 12 ]
- Pharmacokinetics of LCQ908- Average Observed Blood Concentration (Cavg) [ Time Frame: 0, 1, 2, 3, 4, 6, and 24 hours at Week 12 ]Average observed blood concentration measured by (AUC0-24)/24.
- Number of Patients Reported With Any Adverse Event, Serious Adverse Event and Death [ Time Frame: 52 weeks ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Key Inclusion Criteria:
- Written informed consent given before any assessment was performed for Period I.
- Male and female patients ages at least 18 years of age.
- Fasting triglyceride ≥ 8.4 mmol/L (750 mg/dL) at Screening.
-
An established diagnosis of FCS (HLP Type I) confirmed through ultracentrifugation or by documented medical history of a fasting triglyceride ≥ 8.4 mmol/L (750 mg/dL) and by documentation of any of the following at Screening or during the Screening Period:
- Confirmed homozygote or compound heterozygote for known loss-of-function mutations in Type I-causing genes (such as LPL, apo C II, GPIHBP1, or LMF1)
- Post heparin plasma LPL activity of ≤ 20% of normal
- Confirmed presence of LPL inactivating antibodies
- History of pancreatitis.
Key Exclusion Criteria:
- Current pancreatitis, pancreatitis was required to be inactive for at least 1 week prior to the screening Visit.
- Treatment with fish oil preparations within 4 weeks prior to randomization.
- Treatment with bile acid binding resins (i.e., colesevelam, etc.) within 4 weeks prior to randomization.
- Treatment with fibrates within 4 weeks prior to randomization.
- Glybera [alipogene tiparvovec (AAV1-LPLS447X)] gene therapy exposure within the two years prior to screening.
- History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases.
- Any surgical or medical conditions, acute or unstable chronic disease which may, based on the investigator's opinion, jeopardize the patient in case of participation in the study or might significantly alter the absorption, distribution, metabolism or excretion of the study drug.
- History of drug or alcohol abuse within the 12 months prior to randomization or evidence of such abuse at screening.
- Evidence of liver disease or liver injury as indicated by abnormal liver function tests such as aspartate aminotransferase (AST) and alanine aminotransferase (ALT), or serum bilirubin.
- Estimated glomerular filtration rate (eGFR) <30mL/min/1.73m2 or history of chronic renal disease.
- Participation in any clinical investigation within four (4) weeks prior to initial dosing or longer if required by local regulations, or any other limitation of participation based on local regulations.
- History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes.
- Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive HCG laboratory test.
- Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 100 days after discontinuation of investigational study drug.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01514461
United States, Washington | |
Novartis Investigative Site | |
Seatlle, Washington, United States, 98104 | |
Canada, Quebec | |
Novartis Investigative Site | |
Chicoutimi, Quebec, Canada, G7H 7P2 | |
Novartis Investigative Site | |
Ste-Foy, Quebec, Canada, G1V4M6 | |
Canada | |
Novartis Investigative Site | |
Ouest-Montreal, Canada, H2W1R7 | |
France | |
Novartis Investigative Site | |
Bron, France, 69677 | |
Novartis Investigative Site | |
Nantes, France, 44093 | |
Novartis Investigative Site | |
Paris Cedex 13, France, 75651 | |
Germany | |
Novartis Investigative Site | |
Hamburg, Germany, 20246 | |
Novartis Investigative Site | |
Köln, Germany, 50937 | |
Netherlands | |
Novartis Investigative Site | |
Meibergdreef 9, Netherlands, 1105 AZ | |
South Africa | |
Novartis Investigative Site | |
Cape Town, South Africa, 7925 | |
Spain | |
Novartis Investigative Site | |
Malaga, Andalucia, Spain, 29010 | |
Novartis Investigative Site | |
Sevilla, Andalucia, Spain, 41013 | |
United Kingdom | |
Novartis Investigative Site | |
Manchester, United Kingdom, M13 9NT |
Study Director: | Novartis Pharmaceuticals | Novartis Pharmaceuticals |
Responsible Party: | Novartis Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT01514461 History of Changes |
Other Study ID Numbers: |
CLCQ908B2302 2011-005535-68 ( EudraCT Number ) |
First Posted: | January 23, 2012 Key Record Dates |
Results First Posted: | June 3, 2015 |
Last Update Posted: | June 3, 2015 |
Last Verified: | May 2015 |
Keywords provided by Novartis ( Novartis Pharmaceuticals ):
Hyperlipoproteinemia (HLP Type I) Fasting Triglycerides |
Additional relevant MeSH terms:
Hyperlipoproteinemia Type I Syndrome Disease Pathologic Processes Lipid Metabolism, Inborn Errors Metabolism, Inborn Errors |
Genetic Diseases, Inborn Hyperlipoproteinemias Hyperlipidemias Dyslipidemias Lipid Metabolism Disorders Metabolic Diseases |